本文選題：上皮性卵巢癌 + 血清腫瘤標(biāo)記物�。� 參考：《新疆醫(yī)科大學(xué)》2017年碩士論文

【摘要】：目的:探討新型腫瘤標(biāo)記物HE4聯(lián)合CA125及彩色多普勒超聲診斷上皮性卵巢癌的臨床價(jià)值,以及HE4在不同陽(yáng)性區(qū)間的診斷意義。方法:嚴(yán)格按照納入及排除標(biāo)準(zhǔn)選取在2013年1月至2016年1月在新疆醫(yī)科大學(xué)第一附屬醫(yī)院婦科病區(qū)接受手術(shù)治療并根據(jù)術(shù)后常規(guī)病理檢查結(jié)果確診為卵巢上皮性腫瘤的207例患者作為研究對(duì)象,其中卵巢惡性腫瘤組73例、卵巢良性腫瘤組93例、交界性腫瘤組41例,對(duì)所有病人術(shù)前檢測(cè)的血清腫瘤標(biāo)記物及彩色多普勒超聲結(jié)果進(jìn)行回顧性分析。結(jié)果:HE4、CA125及彩色多普勒超聲檢查結(jié)果在惡性組中的陽(yáng)性率明顯高于良性組,差異有統(tǒng)計(jì)學(xué)意義(分別為2cHE4=80.38,P0.005;2cCA125=93.02,P0.005;2c超聲=31.48,P0.005);HE4、CA125及彩色多普勒超聲檢查單獨(dú)診斷上皮性卵巢癌的靈敏度、特異度、準(zhǔn)確度、陽(yáng)性預(yù)測(cè)值、陰性預(yù)測(cè)值分別是75.34%、92.47%、84.94%、88.71%、82.69%;90.41%、84.95%、87.35%、82.50%、91.86%及73.97%、69.89%、71.67%、65.85%、77.38%。三者聯(lián)合診斷上皮性卵巢癌的靈敏度、特異度、準(zhǔn)確度、陽(yáng)性預(yù)測(cè)值、陰性預(yù)測(cè)值分別是98.63%、54.84%、74.10%、63.16%、98.08%。當(dāng)HE4值大于105.10 pmol/L時(shí),卵巢惡性腫瘤組所占比例大于卵巢良性腫瘤組,差異有統(tǒng)計(jì)學(xué)意義(2c=7.22,P0.005)。結(jié)論:新型血清腫瘤標(biāo)記物HE4聯(lián)合CA125及彩色多普勒超聲可顯著提高術(shù)前診斷卵巢癌的正確性,減少漏誤診率,對(duì)早期篩查和診斷卵巢癌、從而及時(shí)治療并改善預(yù)后有著重要的臨床價(jià)值。
[Abstract]:Objective: to evaluate the clinical value of new tumor marker HE4 combined with CA125 and color Doppler ultrasound in the diagnosis of epithelial ovarian cancer and the diagnostic significance of HE4 in different positive regions. Methods: from January 2013 to January 2016, the patients received surgical treatment in the gynecological ward of the first affiliated Hospital of Xinjiang Medical University according to the inclusion and exclusion criteria, and were diagnosed as ovarian epithelium according to the results of postoperative routine pathological examination. A total of 207 cancer patients were included in the study. There were 73 cases of ovarian malignant tumor, 93 cases of benign ovarian tumor and 41 cases of borderline tumor. The results of serum tumor markers and color Doppler ultrasound were analyzed retrospectively. Results the positive rate in malignant group was significantly higher than that in benign group. The difference was statistically significant (2cHE4H _ 4, 80.38, P 0.005 ~ (0.005), P _ (0.005) P _ (0.005), P _ (0.005) ~ (2c), the sensitivity and specificity of color Doppler ultrasound in diagnosing epithelial ovarian cancer, respectively. The accuracy, the positive predictive value, the negative predictive value were 75.34 and 92.477.94, respectively. They were 88.71and 82.690.491.90.41 and 87.35m 82.5091.86% and 73.97765.8577.8577.38. respectively. The results showed that the accuracy, the positive predictive value and the negative predictive value were 88.71% and 84.95%, 87.35%, 82.50% and 77.38%, respectively, and 73.97%, 65.85% and 77.38%, respectively. The sensitivity, specificity, accuracy, positive predictive value and negative predictive value of the three diagnostic methods were 98.63 and 54.84 respectively. When the HE4 value was more than 105.10 pmol/L, the proportion of ovarian malignant tumor group was larger than that of ovarian benign tumor group, and the difference was statistically significant (P 0.005). Conclusion: the new serum tumor marker HE4 combined with CA125 and color Doppler ultrasound can significantly improve the accuracy of preoperative diagnosis of ovarian cancer, reduce the rate of misdiagnosis, early screening and diagnosis of ovarian cancer. It has important clinical value to treat and improve prognosis in time.
【學(xué)位授予單位】：新疆醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類(lèi)號(hào)】：R737.31

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 朱玨;張珂;馬勝林;;CA125單項(xiàng)與多項(xiàng)腫瘤指標(biāo)聯(lián)合檢測(cè)在卵巢癌診斷中的比較[J];國(guó)際婦產(chǎn)科學(xué)雜志;2015年05期

2 武春梅;李霞蓮;李玲;尹莉莉;李倩;;聯(lián)合檢測(cè)腫瘤標(biāo)志物在卵巢腫瘤診斷中的應(yīng)用[J];國(guó)際檢驗(yàn)醫(yī)學(xué)雜志;2014年06期

3 杜春芳;趙霞;賈薇;常彬;;卵巢癌早期診斷血清學(xué)標(biāo)記物研究新進(jìn)展[J];現(xiàn)代腫瘤醫(yī)學(xué);2013年12期

4 鄭麗娥;曲軍英;;血清HE4和CA125聯(lián)合檢測(cè)在卵巢癌早期診斷的臨床價(jià)值[J];中國(guó)醫(yī)藥科學(xué);2013年10期

5 楊佳錦;黃猛;楊靜靜;唐愛(ài)國(guó);;HE4在卵巢癌中的研究進(jìn)展及臨床應(yīng)用[J];國(guó)際檢驗(yàn)醫(yī)學(xué)雜志;2013年09期

6 劉國(guó)林;;血清4項(xiàng)腫瘤標(biāo)志物聯(lián)合檢測(cè)對(duì)卵巢癌的臨床診斷及療效監(jiān)測(cè)價(jià)值[J];檢驗(yàn)醫(yī)學(xué)與臨床;2013年08期

7 李留霞;張?zhí)m蘭;李秀芳;張建營(yíng);王凱娟;代麗萍;王鵬;張毅;;六種腫瘤相關(guān)抗原自身抗體聯(lián)合CA125檢測(cè)對(duì)卵巢癌早期診斷的價(jià)值[J];鄭州大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2013年02期

8 馬二玲;劉越飛;劉曉旭;吳小華;;HE4作為卵巢癌腫瘤標(biāo)志物的研究進(jìn)展[J];河北醫(yī)藥;2012年01期

9 崔恒;謝幸;;正確認(rèn)識(shí)和應(yīng)用腫瘤標(biāo)記物[J];中國(guó)婦產(chǎn)科臨床雜志;2011年05期

10 王俐英;;CA125、CA199聯(lián)合超聲檢查在卵巢惡性腫瘤診斷中的價(jià)值[J];醫(yī)學(xué)臨床研究;2011年03期

，

本文編號(hào)：1911029